Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Seattle Genetics Inc (SGEN)

Seattle Genetics Inc (SGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,322,547
  • Shares Outstanding, K 161,315
  • Annual Sales, $ 654,700 K
  • Annual Income, $ -222,690 K
  • 60-Month Beta 2.06
  • Price/Sales 15.72
  • Price/Cash Flow N/A
  • Price/Book 7.83

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.39
  • Number of Estimates 8
  • High Estimate -0.27
  • Low Estimate -0.43
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -116.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.02 +0.25%
on 07/16/19
74.14 -14.78%
on 06/20/19
-5.32 (-7.77%)
since 06/14/19
3-Month
62.90 +0.45%
on 05/15/19
77.04 -17.99%
on 04/17/19
-13.52 (-17.63%)
since 04/16/19
52-Week
50.71 +24.59%
on 10/30/18
84.37 -25.12%
on 10/03/18
-5.81 (-8.42%)
since 07/16/18

Most Recent Stories

More News
Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates

Seattle Genetics (SGEN) delivered earnings and revenue surprises of 38.46% and 14.25%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

SGEN : 63.18 (-1.27%)
Seattle Genetics: 2Q Earnings Snapshot

BOTHELL, Wash. (AP) _ Seattle Genetics Inc. (SGEN) on Tuesday reported a second-quarter loss of $79.2 million, after reporting a profit in the same period a year earlier.

SGEN : 63.18 (-1.27%)
Seattle Genetics Reports Second Quarter 2019 Financial Results

---Biologics License Application Submitted to FDA for Enfortumab Vedotin to Treat Advanced or Metastatic Urothelial Cancer Based on Results from the EV-201 Pivotal Trial-

SGEN : 63.18 (-1.27%)
Seattle Genetics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 16, 2019 / Seattle Genetics, Inc. (NASDAQ:) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on July 16, 2019 at 4:30 PM Eastern...

SGEN : 63.18 (-1.27%)
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Seattle Genetics, Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced submission of a Biologics License Application for accelerated...

SGEN : 63.18 (-1.27%)
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced submission of a Biologics License Application for accelerated...

ALPMF : 14.0600 (-3.17%)
SGEN : 63.18 (-1.27%)
Notable Tuesday Option Activity: SGEN, OPY, ROKU

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Seattle Genetics Inc , where a total volume of 5,384 contracts has been traded thus...

SGEN : 63.18 (-1.27%)
Earnings Preview: Seattle Genetics (SGEN) Q2 Earnings Expected to Decline

Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SGEN : 63.18 (-1.27%)
Seattle Genetics Falls 3.64% on Heavy Volume: Watch For Potential Rebound

Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $66.54 to a high of $68.00. Yesterday, the shares fell 3.6%, which took the trading range below the 3-day low of...

SGEN : 63.18 (-1.27%)
Natasha A. Hernday Elected to PDL BioPharma's Board of Directors

PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that at its 2019 annual meeting of stockholders held June 20, 2019, the Company's stockholders elected Natasha A. Hernday to the Company's...

PDLI : 3.17 (+1.60%)
SGEN : 63.18 (-1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade SGEN with:

Business Summary

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability...

See More

Key Turning Points

2nd Resistance Point 66.21
1st Resistance Point 64.69
Last Price 63.18
1st Support Level 62.34
2nd Support Level 61.51

See More

52-Week High 84.37
Fibonacci 61.8% 71.51
Fibonacci 50% 67.54
Fibonacci 38.2% 63.57
Last Price 63.18
52-Week Low 50.71

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar